Dare Bioscience, Inc. Increase (Decrease) in Interest Payable, Net
Dare Bioscience, Inc. (DARE) reported Increase (Decrease) in Interest Payable, Net of $323.53 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2026-08-13
- Dare Bioscience, Inc. increase (decrease) in interest payable, net for the quarter ending 2026-06-30 was $165.49K, a 9.68% increase year-over-year.
- Dare Bioscience, Inc. increase (decrease) in interest payable, net for the quarter ending 2026-03-31 was $158.04K, a 34.09% increase year-over-year.
- Dare Bioscience, Inc. increase (decrease) in interest payable, net for the quarter ending 2025-12-31 was $154.55K, a 14.16% increase year-over-year.
- Dare Bioscience, Inc. increase (decrease) in interest payable, net for the quarter ending 2025-09-30 was $149.27K, a 8.23% increase year-over-year.
- Dare Bioscience, Inc. increase (decrease) in interest payable, net for fiscal 2025 was $572.56K, a 9.94% increase from fiscal 2024.
- Dare Bioscience, Inc. increase (decrease) in interest payable, net for fiscal 2024 was $520.82K.
- Dare Bioscience, Inc. increase (decrease) in interest payable, net for fiscal 2023 was $0.00.
- Dare Bioscience, Inc. increase (decrease) in interest payable, net for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 7 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $165.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $323.53K 10-Q · filed 2026-08-13 | $478.08K derived: sum of 3 quarters · filed 2026-08-13 | $627.35K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $158.04K 10-Q · filed 2026-05-14 | $312.60K derived: sum of 2 quarters · filed 2026-05-14 | $461.87K derived: sum of 3 quarters · filed 2026-05-14 | $612.74K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $154.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $303.82K derived: sum of 2 quarters · filed 2026-03-26 | $454.70K derived: sum of 3 quarters · filed 2026-08-13 | $572.56K 10-K · filed 2026-03-26 | |
| 2025-09-30 | $149.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $300.14K derived: sum of 2 quarters · filed 2026-08-13 | $418.01K 10-Q · filed 2025-11-13 | $553.39K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $150.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $268.74K 10-Q · filed 2026-08-13 | $404.12K derived: sum of 3 quarters · filed 2026-08-13 | $542.03K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $117.86K 10-Q · filed 2026-05-14 | $253.25K derived: sum of 2 quarters · filed 2026-05-14 | $391.16K derived: sum of 3 quarters · filed 2026-05-14 | $521.47K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $135.38K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $273.30K derived: sum of 2 quarters · filed 2026-03-26 | $403.60K derived: sum of 3 quarters · filed 2026-03-26 | $520.82K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $137.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $268.22K derived: sum of 2 quarters · filed 2025-11-13 | $385.43K 10-Q · filed 2025-11-13 | $385.43K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $130.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $247.52K 10-Q · filed 2025-08-14 | $247.52K derived: sum of 3 quarters · filed 2025-08-14 | $247.52K derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $117.21K 10-Q · filed 2025-05-13 | $117.21K derived: sum of 2 quarters · filed 2025-05-13 | $117.21K derived: sum of 3 quarters · filed 2025-05-13 | $117.21K derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | ||||
| 2018-12-31 | $0.00 10-K · filed 2019-04-01 | ||||
| 2017-12-31 | -$3.54K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | -$743.00 derived: sum of 2 quarters · filed 2019-04-01 | $17.83K derived: sum of 3 quarters · filed 2019-04-01 | $33.23K 10-K · filed 2019-04-01 | |
| 2017-09-30 | $2.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $21.37K derived: sum of 2 quarters · filed 2018-11-13 | $36.78K 10-Q · filed 2018-11-13 | $48.67K derived: sum of 4 quarters · filed 2018-11-13 | |
| 2017-06-30 | $18.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $33.98K 10-Q · filed 2018-08-13 | $45.87K derived: sum of 3 quarters · filed 2018-08-13 | $56.01K derived: sum of 4 quarters · filed 2018-08-13 | |
| 2017-03-31 | $15.40K 10-Q · filed 2018-05-14 | $27.30K derived: sum of 2 quarters · filed 2018-05-14 | $37.44K derived: sum of 3 quarters · filed 2018-05-14 | ||
| 2016-12-31 | $11.89K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | $22.04K derived: sum of 2 quarters · filed 2018-03-28 | $42.10K 10-K · filed 2018-03-28 | ||
| 2016-09-30 | $10.14K derived: 10-Q 9 month − 8-K/A 6 month · filed 2017-11-13 | $30.20K 10-Q · filed 2017-11-13 | |||
| 2016-06-30 | $20.06K 8-K/A · filed 2017-10-02 | ||||
| 2015-12-31 | $2.96K 8-K/A · filed 2017-10-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |